Apollon Papadimitriou, iOmx CEO

iOmx re­fu­els with $75M+ on its search for im­mune check­point tar­gets on tu­mor cells

While a big chunk of on­col­o­gy re­search is fo­cused on tar­get­ing T-cell reg­u­la­tors to stamp out can­cer, iOmx Ther­a­peu­tics is hom­ing in on im­mune check­point tar­gets on tu­mor cells — and it’s just re­ceived an­oth­er $75.3 mil­lion to fu­el their push to­ward the clin­ic.

iOmx un­veiled the €65 mil­lion Se­ries B round on Tues­day morn­ing, rough­ly five years af­ter emerg­ing from stealth. The new cash will help the start­up put its first can­di­date, an SIK3 ki­nase in­hibitor called IMT-07, in the clin­ic late next year for sol­id tu­mors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.